Literature DB >> 10651940

Production and functional analysis of rat CD59 and chimeric CD59-Crry as active soluble proteins in Pichia pastoris.

R J Quigg1, C He, B K Hack, J J Alexander, B P Morgan.   

Abstract

Crry (CR1-related gene/protein) is a rodent complement regulator that inhibits C3 convertases. CD59 is a conserved protein inhibitor active towards C8 and C9. We have previously produced rat Crry as a recombinant soluble (rs) protein in Pichia pastoris. In this study we produced functionally active rat rsCD59 and a chimeric rsCD59-Crry protein in P. pastoris. The GPI anchor addition site of rat CD59 (Asn-79) was replaced either by a stop codon to produce rsCD59, or with the sequence of the first five short consensus repeats of Crry to produce rsCD59-Crry. Proteins were generated by fermentation and purified by affinity chromatography on an anti-CD59 column. In a standard classical pathway haemolysis assay, all three rs proteins had inhibitory activity, with 50% inhibition at 0.5 microM (rsCrry and rsCD59-Crry) and 4.4 microM (rsCD59). In an assay examining inhibition of C5b-9, in which C5b-7 was first formed, followed by purified C8 and C9, rsCD59 and rsCD59-Crry were active with 50% inhibition at 0.8 microM (rsCD59-Crry) and 1.3 microM (rsCD59). The degree of inhibition was independent of whether the C8 and C9 were of rat or human origin. Therefore, we have produced rsCD59 and rsCD59-Crry in P. pastoris. The rsCD59 retains its inhibitory activity towards C5b-9, while rsCD59-Crry appears to have the combined activities of Crry and CD59. In a haemolytic assay, the inclusion of CD59 to Crry is of no additional benefit to Crry, which may illustrate the overall importance of the C3 convertase step. Yet, inclusion of Crry to CD59 increases the potency of CD59 towards C5b-9.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10651940      PMCID: PMC2327136          DOI: 10.1046/j.1365-2567.2000.00945.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  39 in total

1.  C7*9, a new frequent C7 allele detected by an allotype-specific monoclonal antibody.

Authors:  R Würzner; R Nitze; O Götze
Journal:  Complement Inflamm       Date:  1990

Review 2.  Glomerular injury induced by antibody and complement.

Authors:  R J Quigg
Journal:  Semin Nephrol       Date:  1991-05       Impact factor: 5.299

Review 3.  Mediation of immune glomerular injury.

Authors:  W G Couser
Journal:  J Am Soc Nephrol       Date:  1990-07       Impact factor: 10.121

4.  Molecular characterization of rat Crry: widespread distribution of two alternative forms of Crry mRNA.

Authors:  R J Quigg; C F Lo; J J Alexander; A E Sneed; G Moxley
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

5.  Disulfide bonds are localized within the short consensus repeat units of complement regulatory proteins: C4b-binding protein.

Authors:  J Janatova; K B Reid; A C Willis
Journal:  Biochemistry       Date:  1989-05-30       Impact factor: 3.162

6.  Targeting of functional antibody-CD59 fusion proteins to a cell surface.

Authors:  H F Zhang; J Yu; E Bajwa; S L Morrison; S Tomlinson
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

7.  Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury.

Authors:  K R McCurry; D L Kooyman; C G Alvarado; A H Cotterell; M J Martin; J S Logan; J L Platt
Journal:  Nat Med       Date:  1995-05       Impact factor: 53.440

8.  A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitro.

Authors:  D Christiansen; J Milland; B R Thorley; I F McKenzie; B E Loveland
Journal:  Eur J Immunol       Date:  1996-03       Impact factor: 5.532

9.  The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis.

Authors:  W G Couser; R J Johnson; B A Young; C G Yeh; C A Toth; A R Rudolph
Journal:  J Am Soc Nephrol       Date:  1995-05       Impact factor: 10.121

10.  A novel bifunctional chimeric complement inhibitor that regulates C3 convertase and formation of the membrane attack complex.

Authors:  W L Fodor; S A Rollins; E R Guilmette; E Setter; S P Squinto
Journal:  J Immunol       Date:  1995-11-01       Impact factor: 5.422

View more
  4 in total

1.  Bacterial expression and membrane targeting of the rat complement regulator Crry: a new model anticomplement therapeutic.

Authors:  Deborah A Fraser; Claire L Harris; Richard A G Smith; B Paul Morgan
Journal:  Protein Sci       Date:  2002-10       Impact factor: 6.725

2.  Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo.

Authors:  C L Harris; A S Williams; S M Linton; B P Morgan
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

3.  Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation.

Authors:  Hongbin Song; Chun He; Christian Knaak; Joel M Guthridge; V Michael Holers; Stephen Tomlinson
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

4.  On the three-finger protein domain fold and CD59-like proteins in Schistosoma mansoni.

Authors:  Leonardo P Farias; Greice Krautz-Peterson; Cibele A Tararam; Bogar O Araujo-Montoya; Tatiana R Fraga; Henrique K Rofatto; Floriano P Silva; Lourdes Isaac; Akram A Da'dara; R Alan Wilson; Charles B Shoemaker; Luciana C C Leite
Journal:  PLoS Negl Trop Dis       Date:  2013-10-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.